Atossa Genetics Inc (ATOS) Given Average Rating of “Strong Buy” by Analysts

Share on StockTwits

Shares of Atossa Genetics Inc (NASDAQ:ATOS) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokers have set a twelve-month consensus target price of $7.00 for the company and are anticipating that the company will post ($0.65) EPS for the current quarter, according to Zacks. Zacks has also assigned Atossa Genetics an industry rank of 65 out of 255 based on the ratings given to related companies.

ATOS has been the topic of a number of analyst reports. Maxim Group restated a “buy” rating and set a $5.00 target price on shares of Atossa Genetics in a research report on Wednesday, January 9th. ValuEngine lowered shares of Atossa Genetics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th.

A hedge fund recently raised its stake in Atossa Genetics stock. Virtu Financial LLC increased its position in shares of Atossa Genetics Inc (NASDAQ:ATOS) by 405.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 69,903 shares of the company’s stock after acquiring an additional 56,064 shares during the quarter. Virtu Financial LLC owned approximately 1.24% of Atossa Genetics worth $71,000 as of its most recent filing with the SEC. 11.06% of the stock is currently owned by institutional investors.

Shares of ATOS opened at $1.62 on Thursday. Atossa Genetics has a 1-year low of $0.80 and a 1-year high of $9.96.

Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.01. On average, equities research analysts forecast that Atossa Genetics will post -5.13 earnings per share for the current fiscal year.

About Atossa Genetics

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Read More: How Do Front-End Loads Impact an Investment?

Get a free copy of the Zacks research report on Atossa Genetics (ATOS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.